What topics does this cannabis study cover?

This study covers research on: CBD, Epilepsy, Endocannabinoid.

Where was this research published?

Published in Neurobiology of disease on October 13, 2026.

In Lafora disease mice, CBD and D2 activation restored striatal plasticity

Q: What did this research study find?

In the Lafora disease mouse model, striatal neurons showed **progressive changes in corticostriatal signaling and impaired long-term synaptic plasticity, including LTP**.

D2 dopamine and CB2 cannabinoid receptor cooperation restores striatal LTP in an epilepsy model.

Neurobiology of disease • October 13, 2026 • Highly Relevant

🤖

AI Summary

This ex vivo study used a genetic mouse model of Lafora disease, a drug-resistant neurodegenerative epilepsy, to examine electrical signaling and synaptic plasticity in striatal neurons. The researchers found progressive changes in communication between the cortex and striatum, including impaired long-term potentiation (LTP), a form of synaptic strengthening. They also observed a lower NMDA-to-AMPA receptor ratio and reduced expression of NMDA receptor subunits and dopamine receptors in the mice. The abstract reports no sample size or numerical effect estimates.

In the mouse tissue, a dopamine D2 receptor agonist and cannabidiol (CBD) restored striatal LTP. The authors suggest that dopamine D2 and cannabinoid CB2 receptors may act together in this effect. These laboratory findings point to a role for basal-ganglia signaling in this epilepsy model, but they do not establish that CBD improves epilepsy or cognition in people. This is an abstract-based summary; the abstract does not provide enough detail to assess the size or durability of the effect, and the animal experiment cannot establish clinical benefit.

💡 Key Findings

In the Lafora disease mouse model, striatal neurons showed progressive changes in corticostriatal signaling and impaired long-term synaptic plasticity, including LTP.

Good

70%

The mice had a reduced NMDA/AMPA ratio and reduced expression of NMDA receptor subunits and dopamine receptors in striatal neurons.

Good

70%

In ex vivo recordings, exposure to a D2 receptor agonist and CBD restored striatal LTP; the authors propose a synergistic D2R- and CB2R-dependent action.

Good

60%

📄 Original Abstract

Increasing evidence suggests that subcortical structures contribute to seizure susceptibility and cognitive impairment in several epileptic syndromes. However, research into mechanisms linking neuronal excitability and synaptic dysfunction in epilepsy has mainly focused on the cortex and hippocampus, leaving basal ganglia contributions largely unexplored. Using a genetic murine model of Lafora disease (LD), a drug-resistant form of neurodegenerative epilepsy, we performed ex vivo patch-clamp recordings to assess neuronal excitability, synaptic transmission, and plasticity of striatal medium spiny neurons. Our results reveal progressive alterations in corticostriatal transmission and long-term synaptic plasticity, including long-term potentiation (LTP). Electrophysiological and biochemical assessments showed a reduced NMDA/AMPA ratio and reduced expression of NMDA receptor subunits and dopamine receptors in striatal neurons of LD mice. Exposure to a dopamine D2 receptor agonist and to cannabidiol restored long-term plasticity in LD mice, suggesting a D2R- and CB2R-dependent synergic action on striatal LTP. Our findings highlight basal ganglia dysfunction in experimental epilepsy and suggest an unconventional dopaminergic-endocannabinoid interplay.

Paper Type

📄 Research

Publication

Journal: Neurobiology of disease
Published: October 13, 2026
PMID: 42869231
DOI: 10.1016/j.nbd.2026.107648

Authors (13)

Miriam Sciaccaluga Department of Life Science, Health, and Health Professions, Link University, Rome, Italy; Fondazione Malattie Rare Mauro Baschirotto BIRD Onlus, Longare, VI, Italy; Laboratory of Experimental Neurology, Department of Medicine and Surgery, University of Perugia, Perugia 06132, Italy.
Laura Bellingacci Laboratory of Experimental Neurology, Department of Medicine and Surgery, University of Perugia, Perugia 06132, Italy.
Valentina Imperatore Laboratory of Experimental Neurology, Department of Medicine and Surgery, University of Perugia, Perugia 06132, Italy.
Anna Aurora Taddei Laboratory of Experimental Neurology, Department of Medicine and Surgery, University of Perugia, Perugia 06132, Italy.
Alessandro Tozzi Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia, Perugia 06132, Italy.
+8 more authors